

Inflammatory Bowel Disease in Children

Dr Rajeev Gupta* MBBS, MRCP (UK), FRCPCH (UK), MD.

Triple Accredited MBA (UK OUBS), AEQI, ACEI
Consultant Paediatrician
Chairman Central Specialist Committee Royal College of Paediatrics & Child Health
Vice Chairman CESR Committee, Royal College of Paediatrics
Ex-Chairman Regional Consultant Committee BMA
Recent Chairman Regional Council British Medical Association
Barnsley Foundation Hospital, United Kingdom

***Corresponding author:** Dr Rajeev Gupta, Barnsley Foundation Hospital, Gawber Road, Barnsley S75 2 EP, United Kingdom.
Tel: 01226 432860; Email: rajeev.gupta@nhs.net

Citation: Gupta R (2023) Inflammatory Bowel Disease in Children. Ameri J Clin Med Re: AJCMR-107.

Received Date: March 31st, 2023; **Accepted Date:** April 05th, 2023; **Published Date:** April 10th, 2023

Abstract

Inflammatory bowel disease (IBD) is a chronic and debilitating condition that affects both children and adults. However, the incidence of IBD has been increasing in children in recent years. This article provides an overview of IBD in children, including the epidemiology, pathophysiology, clinical presentation, and management of the disease. The article also highlights recent advances in the understanding of the genetic and environmental factors that contribute to the development of IBD in children. Finally, the article discusses the importance of early diagnosis and comprehensive management of IBD in children to minimize the long-term impact of the disease on their growth and development.

Keywords:

inflammatory bowel disease, children, epidemiology, pathophysiology, clinical presentation, management, genetics, environment

Introduction

Inflammatory bowel disease (IBD) is a chronic and progressive condition that affects the gastrointestinal tract. The two main types of IBD are Crohn's disease (CD) and ulcerative colitis (UC). While IBD can occur at any age, it is increasingly being diagnosed in children. The prevalence of pediatric IBD is estimated to be around 1 in 1000 children in Western countries, with a higher incidence reported in developed nations. The cause of IBD is not completely understood, but it is believed to result from a complex interplay of genetic and environmental factors. Early diagnosis and effective management are essential for improving outcomes in children with IBD.

Aims

To provide a short review and an update of the literature on Paediatric Inflammatory Disease

Methods

This review article is based on a comprehensive literature search of PubMed and other databases using keywords such as inflammatory bowel disease, children, epidemiology, pathophysiology, clinical presentation, management, genetics, and environment. We selected and analysed relevant articles that provided up-to-date information on the topic.

Internet data bases were searched including: PUBMED, Google, Google Scholar ---- The search words that were used included: inflammatory bowel disease in children; Paediatric inflammatory bowel disease, Crohn's disease in children; paediatric Crohn's disease; Ulcerative Colitis in Children;

Paediatric Ulcerative Colitis. Five references were identified which were used to write the short review article.

Results

Paediatric inflammatory bowel disease (IBD) is a chronic inflammatory disorder of the gastrointestinal tract that is increasing in incidence worldwide. IBD is divided into two major types, Crohn's disease (CD) and ulcerative colitis (UC). The incidence of IBD in children is increasing worldwide, with the highest incidence rates reported in North America and Europe [1]. The aetiology of IBD is multifactorial and involves a combination of genetic, environmental, and immunologic factors.

Symptoms of IBD in children may include abdominal pain, diarrhoea, rectal bleeding, weight loss, and poor growth. Diagnosis of IBD in children can be challenging, as symptoms can be non-specific and overlap with other gastrointestinal disorders. A combination of clinical, laboratory, radiological, and endoscopic evaluations is often required to diagnose IBD in children.

The diagnosis of IBD in children can be challenging, and it requires a combination of clinical, radiographic, and endoscopic findings.

The management of IBD in children depends on the severity and extent of the disease, as well as the age and growth status of the child. Mild-to-moderate IBD in children may be managed with lifestyle modifications, such as dietary changes, and medications such as amino salicylates, corticosteroids, and immunomodulators. However, severe or extensive IBD may require hospitalization and more aggressive therapies, such as biologic agents like infliximab.

Recently, there has been increasing interest in the use of dietary therapies for the management of IBD in children. The Crohn's disease exclusion diet (CDED) is one such dietary therapy that has shown promising results in inducing remission in children and adults failing biological therapy. CDED is a structured elimination diet that excludes specific food groups, such as dairy, gluten, and processed foods, while emphasizing the intake of nutrient-dense foods like fruits and vegetables.

Management of IBD in children is aimed at inducing and maintaining remission, preventing disease-related complications, and improving quality of life. The treatment approach is tailored to the individual patient based on disease severity, location, and associated complications. The current therapeutic options for paediatric IBD include aminosalicylates, corticosteroids, immunomodulators, biologics, and surgical interventions [2].

Aminosalicylates, such as mesalamine and sulfasalazine, are effective for mild-to-moderate UC and CD in the colon. Corticosteroids, such as prednisone and budesonide, are used for inducing remission in moderate-to-severe IBD. However, the long-term use of corticosteroids is limited by their significant side effects. Immunomodulators, such as azathioprine, 6-mercaptopurine, and methotrexate, are used for maintenance therapy and steroid-sparing effects. Biologic therapies, including anti-tumour necrosis factor (TNF) agents, such as infliximab and adalimumab, and anti-integrin agents, such as vedolizumab, are effective for moderate-to-severe IBD and for patients who are refractory to conventional therapies [3].

Surgical interventions are reserved for patients who have failed medical therapy or who develop complications, such as strictures, abscesses, or perforation. In UC, total proctocolectomy with ileal pouch-anal anastomosis is the standard surgical treatment. In CD, surgery is tailored to the individual patient and can range from limited resection to total colectomy and proctectomy [4].

In addition to medical and surgical interventions, lifestyle modifications and nutritional support are essential for the management of paediatric IBD. Patients with IBD are at increased risk for malnutrition due to poor dietary intake, nutrient malabsorption, and increased nutrient losses. Nutritional support, including exclusive enteral nutrition (EEN), is effective in inducing remission and improving growth and nutritional status in children with CD. EEN has also been shown to have steroid-sparing effects [5].

IBD is thus a chronic inflammatory condition that can have significant effects on the health and well-being of children. The management of IBD in children requires a comprehensive approach that addresses the physical, psychological, and social aspects of the disease. Advances in treatment modalities, such

as biologic agents and dietary therapies like CDED, are providing new options for the management of IBD in children. With early and effective management, children with IBD can achieve remission and maintain a good quality of life.

The diagnosis and management of paediatric IBD require a multidisciplinary approach, involving paediatric gastroenterologists, radiologists, and surgeons. The treatment approach in children is tailored to the individual child based on disease severity, location, and associated complications.

Conclusion

Inflammatory bowel disease is a chronic and debilitating condition that is increasingly being diagnosed in children. The pathogenesis of IBD in children involves a complex interplay of genetic and environmental factors. Early diagnosis and comprehensive management are essential for improving outcomes in children with IBD. Recent advances in the understanding of the pathogenesis of IBD and the availability of newer treatment options offer hope for better outcomes in the future.

Conflict of Interest - None

Acknowledgements - None

References

1. Benchimol EI, Fortinsky KJ, Gozdyra P, Van den Heuvel M, Van Limbergen J, Griffiths AM. Epidemiology of pediatric inflammatory bowel disease: a systematic review of international trends. *Inflammatory bowel diseases*. 2011;17(1):423-439. DOI: 10.1002/ibd.21349.
2. Turner D, Griffiths AM. Acute severe ulcerative colitis in children: a systematic review. *Inflammatory bowel diseases*. 2011;17(1):440-449. DOI: 10.1002/ibd.21336.
3. Hyams JS, Dubinsky MC, Baldassano RN, Colletti RB, Cucchiara S, Escher JC, et al. Infliximab is not associated with increased risk of malignancy or hemophagocytic lymphohistiocytosis in pediatric patients with inflammatory bowel disease. *Gastroenterology*. 2017;152(8):1901-1914. DOI: 10.1053/j.gastro.2017.02.031.
4. Colombel JF, Narula N, Peyrin-Biroulet L. Management strategies to improve outcomes of patients with inflammatory bowel diseases. *Gastroenterology*. 2017;152(2):351-361. DOI: 10.1053/j.gastro.2016.10.024.
5. Sigall Boneh R, Sarbagili Shabat C, Yanai H, Chermesh I, Ben Avraham S, Boaz M, et al. Dietary therapy with the Crohn's disease exclusion diet is a successful strategy for induction of remission in children and adults failing biological therapy. *Journal of Crohn's and colitis*. 2017;11(10):1205-1212. DOI: 10.1093/ecco-jcc/jjx066.